Clinical Application Study on Tanshinone ⅡA Sodium Sulfonate and Levosimendan in the Treatment of Ischemic Cardiomyopathy

XU Huirong; ZHANG Yingqiang; FAN Shaonan; LU Ning; Lu Lei

doi:10.3639/j.issn.2095-3097.2024.11.050

Abstract：Objective To observe the clinical efficacy,indicators of ventricular remodeling,and inflammation of tanshi-none ⅡA sodium sulfonate combined with levosimendan in the treatment of ischemic cardiomyopathy.Methods 120 patients with ischemic cardiomyopathy treated in Nanjing Central Hospital from August 2022 to December 2023 were selected and di-vided into the observation group and the control group by the random number table method with 60 cases.The control group was treated with levosimendan on the basis of conventional treatment,and the patients in observation group was given tanshi-none ⅡA sodium sulfonate in addition to the treatment in the control group.After 2 weeks of treatment,the clinical efficacy,cardiac function,ventricular remodeling indicators,inflammatory factor indexes,and safety were compared between the two group.Results The overall response rate in the observation group was higher than that in the control group(P<0.05).After treatment,the left ventricular end-diastolic dimension(LVEDD),left ventricular end-systolic dimension(LVESD),as well as serum hypersensitive C-reactive protein(hs-CRP),Interleukin-6(IL-6)of both groups were lower than before treatment,and the observation group was lower than the control group(P<0.05 for all).After treatment,the left ventricular ejection fraction(LVEF)and stroke volume(SV)of both groups were higher than before treatment,and the observation group was higher than the control group(P<0.05 for all);the incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion Tanshinone ⅡA sodium sulfonate combined with levosimendan has a good clinical efficacy in patients with ischemic cardiomyopathy,improves their cardiac function,reduces the inflammatory response,and has a high safety profile.